Pyc Therapeutics Ltd has released a press release.
Cre Enzyme Delivery Provides Validation & Strategic Value
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Dec 2017 Half-year financial statements & Appendix 4D
- Dec Quarterly Update and Appendix 4C
- Federal R&D Tax Credit Received
- FPP Results Effective in Delivering Peptide Cancer Vaccine
- Phylogica Strategic Update - Pivot to Platform
Later from PYC Therapeutics
- Changes to Board and Management
- March 2018 Operational Update and Cashflow
- CEO Update
- Successful In-vivo Results Peptide Vaccine T-Cell Expansion
- Achievement of Major Milestone - In vivo Cre Delivery
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics